Asian Journal of Neurosurgery

: 2020  |  Volume : 15  |  Issue : 2  |  Page : 266--271

The ethical dilemma in the surgical management of low grade gliomas according to the variable availability of resources and surgeon experience

Marshall Norman Lahiff1, Michael George Zaki Ghali2,  
1 School of Law, University of Miami; Walton Lantaff Schoreder and Carson LLP, Miami, Florida, USA
2 Department of Neurological Surgery, Houston Methodist Hospital, Houston, Texas; Department of Neurobiology and Anatomy, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA

Correspondence Address:
Michael George Zaki Ghali
Department of Neurosurgery Surgery, Houston Methodist Hospital, 6560 Fannin Street, Houston, TX 77030


Low grade gliomas (LGGs) affect young individuals in the prime of life. Management may alternatively include biopsy and observation or surgical resection. Recent evidence strongly favors maximal and supramaximal resection of LGGs in optimizing survival metrics. Awake craniotomy with cortical mapping and electrical stimulation along with other preoperative and intraoperative surgical adjuncts, including intraoperative magnetic resonance and diffusion tensor imaging, facilitates maximization of resection and eschews precipitating neurological deficits. Intraoperative imaging permits additional resection of identified residual to be completed within the same surgical session, improving extent of resection and consequently progression free and overall survival. These resources are available in only a few centers throughout the United States, raising an ethical dilemma as to where patients harboring LGGs should most appropriately be treated.

How to cite this article:
Lahiff MN, Ghali MG. The ethical dilemma in the surgical management of low grade gliomas according to the variable availability of resources and surgeon experience.Asian J Neurosurg 2020;15:266-271

How to cite this URL:
Lahiff MN, Ghali MG. The ethical dilemma in the surgical management of low grade gliomas according to the variable availability of resources and surgeon experience. Asian J Neurosurg [serial online] 2020 [cited 2021 Jun 18 ];15:266-271
Available from:

Full Text


Approximately 1600 cases of low grade gliomas (LGGs) are diagnosed annually in the pediatric population and 5000 cases in adults.[1],[2] The natural history of LGG follows a course that is ultimately fatal with mean age at diagnosis of approximately 41 years.[3] This age is often the most productive part of life, often with a spouse and children involved. Therefore, treatment decisions are extremely important, since outcomes critically impact on the patient's quality of life[4],[5],[6] and poor decisions could putatively have significant ramifications to the individual and family. We will thus perform a thorough review of the literature in order to evaluate the argument that patients harboring LGGs should receive multidisciplinary treatment at centers capable of providing all the surgical adjunctive resources facilitating preoperative and intraoperative determination of tumor structure properties,[7],[8],[9],[10],[11],[12],[13],[14],[15],[16],[17],[18],[19] relationship to eloquent cortical structures[20],[21],[22],[23] and white matter tracts,[24],[25],[26],[27] and completeness of extirpation, in order to safely maximize the extent of resection.[6],[28],[29],[30],[31],[32],[33],[34],[35],[36],[37],[38],[39],[40],[41],[42],[43],[44] If this is true, it should pose an ethical dilemma regarding where, and by which surgeon, the operation is most appropriately performed.[45]

 Supratotal and Maximal Safe Resection of Low Grade Gliomas

The optimal treatment of LGGs remains controversial and the most appropriate management of these tumors is not entirely clear, though a plethora of studies have made significant strides and efforts in order to precisely elucidate ideal therapeutic strategies.[1],[2],[5],[25],]29],[31],[32],[33],[34],[36],[38],[40],[41],[43],[46],[47],[48],[49],[50],[51],[52],[53],[54],[55],[56],[57],[58] For symptomatic LGGs in noneloquent parenchyma, there is general agreement that an aggressive resection proves ideal,[4],[6],[28],[35],[37],[38],[41],[43],[44] but for lesions that are asymptomatic, slow-growing, and/or located in eloquent cortex, the optimal management strategy remains disputed, with conservative[58] or surgical therapy[1],[4],[5],[45],[47],[49] alternatively appropriate. Multiple therapeutic paradigms exist in order to effectively manage these lesions,[47] including observation (clinical and imaging surveillance) alone,[59] biopsy and observation, biopsy and radiotherapy, extirpation resection[60] without or with neoadjuvant chemotherapy (e.g., temozolomide)[29],[38] followed by observation, surgical resection followed by radiotherapy,[52] and laser interstitial thermal therapy.[56],[61]

While earlier studies had supported observation as an equally viable alternative to surgical resection,[59] a subsequent study carried out in Norway demonstrated significantly greater 5 year overall survival (74%) in patients with diffuse LGG following resection compared to observation (60%).[60] Moreover, recent evidence suggests upfront maximal safe resection (MSR) not only alters the natural history of the disease, but also additionally improves overall survival and malignant progression-free survival, as well as seizure control.[4],[30],[35],[41],[44],[60],[61],[62],[63],[64] Furthermore, authors have described supratotal resection, whereby maximal resection is extended to include a rim of radiographically and grossly normal tissue, a strategy having become an attractive concept well demonstrated to improve outcomes.[4],[6],[44]

 Surgical Resources Maximizing the Resection of Low Grade Gliomas

Based on the aforementioned studies, and if the recent data are correct, a maximal/gross total or supratotal resection should be the goal in patients with LGGs in order to optimize clinical outcomes.[4],[6],[28],[35],[37],[38],[41],[43],[44] The natural history of LGGs may be significantly improved with a more aggressive or even a supratotal resection.[4],[6],[44] An oncofunctional balance must be made, wherein eloquent parenchyma is preserved in order to prevent deficits,[39],[65] while achieving a maximal resection in order to improve overall survival.[6] In order to reliably obtain these goals safely, especially in regions adjacent to eloquent cortex, use of numerous preoperative and intra-operative modalities proves requisite (Tovar Spinoza et al., 2016).[4],[5],[6],[39],[44],[61] Preoperative resources include functional magnetic resonance imaging (MRI) to evaluate functional cortex,[20],[21],[22],[23] WADA testing to evaluate speech dominance, and diffusion tensor imaging and fiber tractography in order to accurately locate deep fiber tracts [Figure 1].[24],[25],[26],[27] The intraoperative adjunct armamentarium includes neuronavigation,[21],[66] awake craniotomy with intraoperative cortical and subcortical mapping,[8],[10],[11],[14],[15],[23],[67] intraoperative tumor staining dyes (e.g., 5-delta-aminolevulinic acid) to delineate tumor from normal brain,[68],[69],[70],[71] and intraoperative MRI to detect tumor residual following initial resection,[7],[8],[9],[10],[11],[12],[13],[14],[15],[16],[17],[18],[19] all of which prove useful alone or in combination to facilitate MSR of diffuse low grade and high grade gliomas.[4],[6],32-34,[39],[44] Additionally and indispensably, the surgeon's experience operatively and with the foregoing modalities is highly variable and arguably critical in determining the degree of MSR achievable and optimizing patient outcomes, a general principle in neurological[69],[70],[71] and general[75],[76],[77],[78],[79] surgery. Critically, this may bear significant medicolegal implications as well, since surgeon inexperience accounts for approximately 40%–60% of factors contributing to medical error, resulting in malpractice cases.[80],[81]{Figure 1}

 Surgeon Experience and Patient Outcomes

The importance of surgeon experience on survival and functional outcomes cannot be overemphasized. Improved outcomes for complex surgical problems are consistently correlated with surgeon experience and hospital volume in both neurological[45],[72],[73] as well as general[75],[76],[77],[78],[79] surgery, especially for more complex and challenging pathologies.[74],[82] For instance, greater surgeon experience correlates with reduced mortality in laparoscopic major hepatectomies,[83] reduced postoperative complications and mortality following laparoscopic colorectal operative intervention,[84] enhanced recovery of urinary continence following robotic-assisted radical prostatectomy,[85] higher endocrinological cure rates for transsphenoidal resection of pituitary adenoma,[74] reduced postoperative corneal edema following cataract surgery,[86] reduced postoperative mortality following pancreaticoduodenectomy,[82] reduced postoperative complications following laparoscopic cholecystectomy,[87] and fewer complications following shoulder arthroplasty and hemiarthroplasty.[88]


Neurosurgical outcomes obtained in the treatment of low grade gliomas are significantly facilitated by the use of awake craniotomy with cortical stimulation mapping, neuronavigation guided craniotomy, surgical approach, and microsurgical tumor removal, diffusion tensor imaging to identify the relationship of eloquent white matter tracts with respect to the tumor, intraoperative magnetic resonance imaging to guide tumor resection and determine extent of resection prior to closure of craniotomy, and d-aminolevulinic acid staining to distinguish between tumor tissue and normal cerebral parenchyma (Duffau, 2017, 2018, 2019; de Leeuw and Vogelbaum, 2019; Dimou et al., 2019; D'Souza et al., 2019).[89],[90],[91],[92],[93],[94],[95] Since diffuse LGGs bear fatal consequences which can be facilely delayed with optimal and ideal treatment, an ethical dilemma becomes clearly evident. This dilemma is present in the United States of America and throughout the world.[28] Despite the extensive evidence arguing in favor of, and supporting, more aggressive and earlier resection in order to improve outcomes, LGGs are treated at a variety of facilities across the world and the United States of America without these operative resources or surgeon experience to optimize the ultimate outcome for the patient due to limited availability. In third world nations with facilities lacking all, or the majority, of these resources, it may be ethical to operate on LGGs when the differential outcome may otherwise be fatal to this young population. However, in the United States of America, which spends close to 18% of its gross domestic product on healthcare, with amply equipped facilities and experienced surgeons readily available nationally, a dilemma arises as to whether it is ethical to operate on these lesions without the aid and benefit of these resources. Further studies rigorously evaluating the survival advantage conferred by the use of each of these surgical adjuncts and resources will critically inform this heated debate.

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest.


1McKhann GM, Duffau H. Low-grade glioma: Epidemiology, pathophysiology, clinical features, and treatment. Neurosurg Clin N Am 2019;30:xiii-xiv.
2Diwanji TP, Engelman A, Snider JW, Mohindra P. Epidemiology, diagnosis, and optimal management of glioma in adolescents and young adults. Adolesc Health Med Ther 2017;8:99-113.
3Claus EB, Walsh KM, Wiencke JK, Molinaro AM, Wiemels JL, Schildkraut JM, et al. Survival and low-grade glioma: The emergence of genetic information. Neurosurg Focus 2015;38:E6.
4Duffau H. Long-term outcomes after supratotal resection of diffuse low-grade gliomas: A consecutive series with 11-year follow-up. Acta Neurochir (Wien) 2016;158:51-8.
5Duffau H. Awake mapping is not an additional surgical technique but an alternative philosophy in the management of low-grade glioma patients. Neurosurg Rev 2018;41:689-91.
6Lima GL, Dezamis E, Corns R, Rigaux-Viode O, Moritz-Gasser S, Roux A, et al. Surgical resection of incidental diffuse gliomas involving eloquent brain areas. Rationale, functional, epileptological and oncological outcomes. Neurochirurgie 2017;63:250-8.
7Incekara F, Olubiyi O, Ozdemir A, Lee T, Rigolo L, Golby A. The value of pre- and intraoperative adjuncts on the extent of resection of hemispheric low-grade gliomas: A retrospective analysis. J Neurol Surg A Cent Eur Neurosurg 2016;77:79-87.
8Leuthardt EC, Lim CC, Shah MN, Evans JA, Rich KM, Dacey RG, et al. Use of movable high-field-strength intraoperative magnetic resonance imaging with awake craniotomies for resection of gliomas: Preliminary experience. Neurosurgery 2011;69:194-205.
9Lu J, Wu J, Yao C, Zhuang D, Qiu T, Hu X, et al. Awake language mapping and 3-Tesla intraoperative MRI-guided volumetric resection for gliomas in language areas. J Clin Neurosci 2013;20:1280-7.
10Nabavi A, Goebel S, Doerner L, Warneke N, Ulmer S, Mehdorn M. Awake craniotomy and intraoperative magnetic resonance imaging: Patient selection, preparation, and technique. Top Magn Reson Imaging 2009;19:191-6.
11Tuominen J, Yrjänä S, Ukkonen A, Koivukangas J. Awake craniotomy may further improve neurological outcome of intraoperative MRI-guided brain tumor surgery. Acta Neurochir (Wien) 2013;155:1805-12.
12Weingarten DM, Asthagiri AR, Butman JA, Sato S, Wiggs EA, Damaska B, et al. Cortical mapping and frameless stereotactic navigation in the high-field intraoperative magnetic resonance imaging suite. J Neurosurg 2009;111:1185-90.
13Goebel S, Nabavi A, Schubert S, Mehdorn HM. Patient perception of combined awake brain tumor surgery and intraoperative 1.5-T magnetic resonance imaging: The Kiel experience. Neurosurgery 2010;67:594-600.
14Parney IF, Goerss SJ, McGee K, Huston J 3rd, Perkins WJ, Meyer FB. Awake craniotomy, electrophysiologic mapping, and tumor resection with high-field intraoperative MRI. World Neurosurg 2010;73:547-51.
15Maldaun MV, Khawja SN, Levine NB, Rao G, Lang FF, Weinberg JS, et al. Awake craniotomy for gliomas in a high-field intraoperative magnetic resonance imaging suite: Analysis of 42 cases. J Neurosurg 2014;121:810-7.
16Choudhri AF, KlimoPJr., Auschwitz TS, Whitehead MT, Boop FA. 3T intraoperative MRI for management of pediatric CNS neoplasms. AJNR Am J Neuroradiol 2014;35:2382-7.
17Roder C, Breitkopf M, Ms, Bisdas S, Freitas Rda S, Dimostheni A, et al. Beneficial impact of high-field intraoperative magnetic resonance imaging on the efficacy of pediatric low-grade glioma surgery. Neurosurg Focus 2016;40:E13.
18Ghinda D, Zhang N, Lu J, Yao CJ, Yuan S, Wu JS. Contribution of combined intraoperative electrophysiological investigation with 3-T intraoperative MRI for awake cerebral glioma surgery: Comprehensive review of the clinical implications and radiological outcomes. Neurosurg Focus 2016;40:E14.
19Claus EB, Horlacher A, Hsu L, Schwartz RB, Dello-Iacono D, Talos F,et al. Survival rates in patients with low-grade glioma after intraoperative magnetic resonance image guidance. Cancer 2005;103:1227-33.
20Izutsu N, Kinoshita M, Yanagisawa T, Nakanishi K, Sakai M, Kishima H. Preservation of motor function after resection of lower-grade glioma at the precentral gyrus and prediction by presurgical functional magnetic resonance imaging and magnetoencephalography. World Neurosurg 2017;107:1045:e5-8.
21Berntsen EM, Gulati S, Solheim O, Kvistad KA, Torp SH, Selbekk T, et al. Functional magnetic resonance imaging and diffusion tensor tractography incorporated into an intraoperative 3-dimensional ultrasound-based neuronavigation system: Impact on therapeutic strategies, extent of resection, and clinical outcome. Neurosurgery 2010;67:251-64.
22Kumar A, Chandra PS, Sharma BS, Garg A, Rath GK, Bithal PK, et al. The role of neuronavigation-guided functional MRI and diffusion tensor tractography along with cortical stimulation in patients with eloquent cortex lesions. Br J Neurosurg 2014;28:226-33.
23Lu JF, Zhang H, Wu JS, Yao CJ, Zhuang DX, Qiu TM, et al. “Awake” intraoperative functional MRI (ai-fMRI) for mapping the eloquent cortex: Is it possible in awake craniotomy? Neuroimage Clin 2012;2:132-42.
24Bello L, Castellano A, Fava E, Casaceli G, Riva M, Scotti G, et al. Intraoperative use of diffusion tensor imaging fiber tractography and subcortical mapping for resection of gliomas: Technical considerations. Neurosurg Focus 2010;28:E6.
25Darlix A, Mandonnet E, Freyschlag CF, Pinggera D, Forster MT, Voss M, et al. Chemotherapy and diffuse low-grade gliomas: A survey within the European Low-Grade Glioma Network. Neurooncol Pract 2019;6:264-73.
26Yan JL, van der Hoorn A, Larkin TJ, Boonzaier NR, Matys T, Price SJ. Extent of resection of peritumoral diffusion tensor imaging-detected abnormality as a predictor of survival in adult glioblastoma patients. J Neurosurg 2017;126:234-41.
27Castellano A, Bello L, Michelozzi C, Gallucci M, Fava E, Iadanza A, et al. Role of diffusion tensor magnetic resonance tractography in predicting the extent of resection in glioma surgery. Neuro Oncol 2012;14:192-202.
28Mirza AF, Shamim MS. Extent of resection and timing of surgery in adult low grade glioma. J Pak Med Assoc 2017;67:959-61.
29Al-Tamimi YZ, Palin MS, Patankar T, MacMullen-Price J, O'Hara DJ, Loughrey C, et al. Low-grade glioma with foci of early transformation does not necessarily require adjuvant therapy after radical surgical resection. World Neurosurg 2018;110:e346-54.
30Chang EF, Potts MB, Keles GE, Lamborn KR, Chang SM, Barbaro NM, et al. Seizure characteristics and control following resection in 332 patients with low-grade gliomas. J Neurosurg 2008;108:227-35.
31Corrivetti F, Herbet G, Moritz-Gasser S, Duffau H. Prosopagnosia induced by a left anterior temporal lobectomy following a right temporo-occipital resection in a multicentric diffuse low-grade glioma. World Neurosurg 2017;97:756.e1-5.
32Duffau H. Is non-awake surgery for supratentorial adult low-grade glioma treatment still feasible? Neurosurg Rev 2018a; 41:133-9.
33Duffau H. Paradoxes of evidence-based medicine in lower-grade glioma: To treat the tumor or the patient? Neurology 2018b; 91:657-62.
34Duffau H. Diffuse low-grade glioma, oncological outcome and quality of life: A surgical perspective. Curr Opin Oncol 2018c; 30:383-9.
35Englot DJ, Han SJ, Berger MS, Barbaro NM, Chang EF. Extent of surgical resection predicts seizure freedom in low-grade temporal lobe brain tumors. Neurosurgery 2012;70:921-8.
36Hendriks EJ, Idema S, Hervey-Jumper SL, Bernat AL, Zwinderman AH, Barkhof F, et al. Preoperative resectability estimates of nonenhancing glioma by neurosurgeons and a resection probability map. Neurosurgery 2019;85:E304-13.
37Jakola AS, Myrmel KS, Kloster R, Torp SH, Lindal S, Unsgård G, et al. Comparison of a strategy favoring early surgical resection vs. a strategy favoring watchful waiting in low-grade gliomas. JAMA 2012;308:1881-8.
38Jo J, Williams B, Smolkin M, Wintermark M, Shaffrey ME, Lopes MB, et al. Effect of neoadjuvant temozolomide upon volume reduction and resection of diffuse low-grade glioma. J Neurooncol 2014;120:155-61.
39McGirt MJ, Chaichana KL, Attenello FJ, Weingart JD, Than K, Burger PC, et al. Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating lowgrade gliomas. Neurosurgery 2008;63:700-7.
40Picart T, Herbet G, Moritz-Gasser S, Duffau H. Iterative Surgical Resections of Diffuse Glioma With Awake Mapping: How to Deal With Cortical Plasticity and Connectomal Constraints? Neurosurgery 2019;85:105-16.
41Picart T, Duffau H. Awake resection of a left operculo-insular low-grade glioma guided by cortico-subcortical mapping. Neurosurg Focus 2018;45:V1.
42Smith JS, Chang EF, Lamborn KR, Chang SM, Prados MD, Cha S, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol 2008;26:1338-45.
43Still ME, Roux A, Huberfeld G, Bauchet L, Baron MH, Fontaine D, et al. Extent of resection and residual tumor thresholds for postoperative total seizure freedom in epileptic adult patients harboring a supratentorial diffuse low-grade glioma. Neurosurgery 2019;85:E332-40.
44Yordanova YN, Moritz-Gasser S, Duffau H. Awake surgery for WHO Grade II gliomas within “noneloquent” areas in the left dominant hemisphere: Toward a “supratotal” resection. Clinical article. J Neurosurg 2011;115:232-9.
45Best B, Nguyen HS, Doan NB, Gelsomino M, Shabani S, Ahmadi Jazi G, et al. Gliomas: Survival differences between metropolitan and non-metropolitan counties. J Neurosurg Sci 2019;63:114-120.
46Almairac F, Duffau H, Herbet G. Contralesional macrostructural plasticity of the insular cortex in patients with glioma: A VBM study. Neurology 2018;91:e1902-8.
47Vanacôr C, Duffau H. Analysis of legal, cultural, and socioeconomic parameters in low-grade glioma management: Variability across countries and implications for awake surgery. World Neurosurg 2018;120:47-53.
48Coget A, Deverdun J, Bonafé A, van Dokkum L, Duffau H, Molino F, et al. Transient immediate postoperative homotopic functional disconnectivity in low-grade glioma patients. Neuroimage Clin 2018;18:656-62.
49Mandonnet E, Duffau H. An attempt to conceptualize the individual onco-functional balance: Why a standardized treatment is an illusion for diffuse low-grade glioma patients. Crit Rev Oncol Hematol 2018;122:83-91.
50Peeters S, Pagès M, Gauchotte G, Miquel C, Cartalat-Carel S, Guillamo JS, et al. Interactions between glioma and pregnancy: Insight from a 52-case multicenter series. J Neurosurg 2018;128:3-13.
51Oberheim Bush NA, Chang S. Treatment Strategies for Low-Grade Glioma in Adults. J Oncol Pract 2016;12:1235-41.
52Tovar-Spinoza Z, Choi H. MRI-guided laser interstitial thermal therapy for the treatment of low-grade gliomas in children: A case-series review, description of the current technologies and perspectives. Childs Nerv Syst 2016;32:1947-56.
53Kaya V, Aksu MG, Korcum AF, Ozdemir B, Ceçen Y, Sindir B, et al. Clinical prognostic factors of adjuvant radiation therapy for low-grade gliomas: Results of 10 years survival. Int J Clin Exp Med 2014;7:1336-43.
54Hurwitz MD. Today's thermal therapy: Not your father's hyperthermia: Challenges and opportunities in application of hyperthermia for the 21st century cancer patient. Am J Clin Oncol 2010;33:96-100.
55Schwarzmaier HJ, Eickmeyer F, von Tempelhoff W, Fiedler VU, Niehoff H, Ulrich SD, et al. MR-guided laser-induced interstitial thermotherapy of recurrent glioblastoma multiforme: Preliminary results in 16 patients. Eur J Radiol 2006;59:208-15.
56Sloan AE, Ahluwalia MS, Valerio-Pascua J, Manjila S, Torchia MG, Jones SE, et al. Results of the NeuroBlate System first-in-humans Phase I clinical trial for recurrent glioblastoma: Clinical article. J Neurosurg 2013;118:1202-19.
57Mohammadi AM, Hawasli AH, Rodriguez A, Schroeder JL, Laxton AW, Elson P, et al. The role of laser interstitial thermal therapy in enhancing progression-free survival of difficult-to-access high-grade gliomas: A multicenter study. Cancer Med 2014;3:971-9.
58Carpentier A, Chauvet D, Reina V, Beccaria K, Leclerq D, McNichols RJ, et al. MR-guided laser-induced thermal therapy (LITT) for recurrent glioblastomas. Lasers Surg Med 2012;44:361-8.
59Reijneveld JC, Sitskoorn MM, Klein M, Nuyen J, Taphoorn MJ. Cognitive status and quality of life in patients with suspected versus proven low-grade gliomas. Neurology 2001;56:618-23.
60Jakola AS, Skjulsvik AJ, Myrmel KS, Sjåvik K, Unsgård G, Torp SH, et al. Surgical resection versus watchful waiting in low-grade gliomas. Ann Oncol 2017;28:1942-8.
61Tovar-Spinoza Z, Choi H. MRI-guided laser interstitial thermal therapy for the treatment of low-grade gliomas in children: A case-series review, description of the current technologies and perspectives. Childs Nerv Syst.2016;32:1947-56.
62Roelz R, Strohmaier D, Jabbarli R, Kraeutle R, Egger K, Coenen VA, et al. Residual tumor volume as best outcome predictor in low grade glioma – A nine-years near-randomized survey of surgery vs. biopsy. Sci Rep 2016;6:32286.
63You G, Huang L, Yang P, Zhang W, Yan W, Wang Y, et al. Clinical and molecular genetic factors affecting postoperative seizure control of 183 Chinese adult patients with low-grade gliomas. Eur J Neurol 2012;19:298-306.
64Gunnarsson T, Olafsson E, Sighvatsson V, Hannesson B. Surgical treatment of patients with low-grade astrocytomas and medically intractable seizures. Acta Neurol Scand 2002;105:289-92.
65Gulati S, Jakola AS, Nerland US, Weber C, Solheim O. The risk of getting worse: surgically acquired deficits, perioperative complications, and functional outcomes after primary resection of glioblastoma. World Neurosurg 2011;76:572-9.
66Mikuni N, Okada T, Enatsu R, Miki Y, Hanakawa T, Urayama S,et al. Clinical impact of integrated functional neuronavigation and subcortical electrical stimulation to preserve motor function during resection of brain tumors. J Neurosurg 2007;106:593-8.
67Alimohamadi M, Shirani M, Shariat Moharari R, Pour-Rashidi A, Ketabchi M, Khajavi M, et al. Application of awake craniotomy and intraoperative brain mapping for surgical resection of insular gliomas of the dominant hemisphere. World Neurosurg 2016;92:151-8.
68Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: A randomised controlled multicentre phase III trial. Lancet Oncol 2006;7:392-401.
69Schucht P, Beck J, Abu-Isa J, Andereggen L, Murek M, Seidel K, et al. Gross total resection rates in contemporary glioblastoma surgery: Results of an institutional protocol combining 5-aminolevulinic acid intraoperative fluorescence imaging and brain mapping. Neurosurgery 2012;71:927-35.
70Sanai N, Snyder LA, Honea NJ, Coons SW, Eschbacher JM, Smith KA, et al. Intraoperative confocal microscopy in the visualization of 5-aminolevulinic acid fluorescence in low-grade gliomas. J Neurosurg 2011b;115:740-8.
71Chan DT, Yi-Pin Sonia H, Poon WS. 5-Aminolevulinic acid fluorescence guided resection of malignant glioma: Hong Kong experience. Asian J Surg 2018;41:467-72.
72Titsworth WL, Scott RM, Smith ER. National analysis of 2454 pediatric moyamoya admissions and the effect of hospital volume on outcomes. Stroke 2016;47:1303-11.
73Kalani MY, Rangel-Castilla L, Ramey W, Nakaji P, Albuquerque FC, McDougall CG, et al. Indications and results of direct cerebral revascularization in the modern era. World Neurosurg 2015;83:345-50.
74Bokhari AR, Davies MA, Diamond T. Endoscopic transsphenoidal pituitary surgery: A single surgeon experience and the learning curve. Br J Neurosurg 2013;27:44-9.
75Amato L, Colais P, Davoli M, Ferroni E, Fusco D, Minozzi S, et al. Volume and health outcomes: Evidence from systematic reviews and from evaluation of Italian hospital data. Epidemiol Prev 2013;37:1-00.
76Archampong D, Borowski D, Wille-Jørgensen P, Iversen LH. Workload and surgeon's specialty for outcome after colorectal cancer surgery. Cochrane Database Syst Rev 2012;3:CD005391.
77Modrall JG, Rosero EB, Chung J, Arko FR 3rd, Valentine RJ, Clagett GP, et al. Defining the type of surgeon volume that influences the outcomes for open abdominal aortic aneurysm repair. J Vasc Surg 2011;54:1599-604.
78Modrall JG, Minter RM, Minhajuddin A, Eslava-Schmalbach J, Joshi GP, Patel S, et al. The surgeon volume-outcome relationship: not yet ready for policy. Ann Surg 2018;267:863-7.
79Young EL, Holt PJ, Poloniecki JD, Loftus IM, Thompson MM. Meta-analysis and systematic review of the relationship between surgeon annual caseload and mortality for elective open abdominal aortic aneurysm repairs. J Vasc Surg 2007;46:1287-94.
80Rogers SO Jr., Gawande AA, Kwaan M, Puopolo AL, Yoon C, Brennan TA, et al. Analysis of surgical errors in closed malpractice claims at 4 liability insurers. Surgery 2006;140:25-33.
81Somville FJ, van Sprundel M, Somville J. Analysis of surgical errors in malpractice claims in Belgium. Acta Chir Belg 2010;110:11-8.
82Schmidt CM, Turrini O, Parikh P, House MG, Zyromski NJ, Nakeeb A, et al. Effect of hospital volume, surgeon experience, and surgeon volume on patient outcomes after pancreaticoduodenectomy: A single-institution experience. Arch Surg 2010;145:634-40.
83Goh BK, Teo JY, Lee SY, Kam JH, Cheow PC, Jeyaraj P, et al. Critical appraisal of the impact of individual surgeon experience on the outcomes of laparoscopic liver resection in the modern era: Collective experience of multiple surgeons at a single institution with 324 consecutive cases. Surg Endosc 2018;32:1802-11.
84Gani F, Cerullo M, Zhang X, Canner JK, Conca-Cheng A, Hartzman AE, et al. Effect of surgeon “experience” with laparoscopy on postoperative outcomes after colorectal surgery. Surgery 2017;162:880-90.
85Fossati N, Di Trapani E, Gandaglia G, Dell'Oglio P, Umari P, Buffi NM, et al. Assessing the impact of surgeon experience on urinary continence recovery after robot-assisted radical prostatectomy: Results of four high-volume surgeons. J Endourol 2017;31:872-7.
86Lhuillier L, Jeancolas AL, Renaudin L, Goetz C, Ameloot F, Premy S, et al. Impact of ophthalmic surgeon experience on early postoperative central corneal thickness after cataract surgery. Cornea 2017;36:541-5.
87Hobbs MS, Mai Q, Knuiman MW, Fletcher DR, Ridout SC. Surgeon experience and trends in intraoperative complications in laparoscopic cholecystectomy. Br J Surg 2006;93:844-53.
88Hammond JW, Queale WS, Kim TK, McFarland EG. Surgeon experience and clinical and economic outcomes for shoulder arthroplasty. J Bone Joint Surg Am 2003;85:2318-24.
89Duffau H. Higher-Order Surgical Questions for Diffuse Low-Grade Gliomas: Supramaximal Resection, Neuroplasticity, and Screening. Neurosurg Clin N Am 2019;30:119-28.
90Duffau H. Diffuse low-grade glioma, oncological outcome and quality of life: a surgical perspective. Curr Opin Oncol 2018;30:383-9.
91Duffau H. Mapping the connectome in awake surgery for gliomas: an update. J Neurosurg Sci 2017;61:612-60.
92de Leeuw CN, Vogelbaum MA. Supratotal resection in glioma: a systematic review. Neuro Oncol 2019;21:179-88.
93Dimou J, Beland B, Kelly J. Supramaximal resection: A systematic review of its safety, efficacy and feasibility in glioblastoma. J Clin Neurosci 2019. p. S0967-5868.
94D'Souza S, Ormond DR, Costabile J, Thompson JA. Fiber-tract localized diffusion coefficients highlight patterns of white matter disruption induced by proximity to glioma. PLoS One 2019;14:e0225323.
95Duffau H. Is non-awake surgery for supratentorial adult low-grade glioma treatment still feasible? Neurosurg Rev 2018;4:133-9.